Boston Scientific Quarterly Cash Flow Statement
NYSE: BSXHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Boston Scientific free cash flow
In the quarter ended Jun 30, 2026, Boston Scientific generated $1.47 billion of operating cash flow and spent $195.0 million on capital expenditures. That left free cash flow of $1.28 billion, a free-cash-flow margin of 23.5% of revenue. Free cash flow was up 13.3% from the prior year's $1.13 billion.
Summary generated from market data by MetaCap's automated system. Methodology
Boston Scientific cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 905.00M | 1.34B | 670.00M | 755.00M | 795.00M | 672.00M | 562.00M | 468.00M | 322.00M | 493.00M | 504.00M | 504.00M |
| Net Income growth (YoY) | +13.84% | +99.26% | +19.22% | +61.32% | +146.89% | +36.31% | +11.51% | -7.14% | +19.26% | +57.01% | +260.00% | +168.09% |
| Depreciation & Amortization | 355.00M | 351.00M | 365.00M | 342.00M | 336.00M | 325.00M | 348.00M | 306.00M | 311.00M | 304.00M | 313.00M | 300.00M |
| Stock-Based Compensation | 87.00M | 83.00M | 71.00M | 79.00M | 75.00M | 74.00M | 69.00M | 68.00M | 66.00M | 63.00M | 59.00M | 59.00M |
| Change in Working Capital | 74.00M | -915.00M | 155.00M | 44.00M | 233.00M | -678.00M | 324.00M | 166.00M | -209.00M | -743.00M | -57.00M | -176.00M |
| Operating Cash Flow | 1.47B | 348.00M | 1.36B | 1.34B | 1.29B | 541.00M | 1.46B | 1.00B | 813.00M | 164.00M | 957.00M | 698.00M |
| Capital Expenditures | -195.00M | -177.00M | -351.00M | -181.00M | -157.00M | -187.00M | -277.00M | -179.00M | -155.00M | -179.00M | -267.00M | -190.00M |
| Investing Cash Flow | -1.96B | -591.00M | -512.00M | -502.00M | -1.13B | -500.00M | -3.70B | -1.43B | -271.00M | -285.00M | -1.05B | -197.00M |
| Dividends Paid | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt Issued | 0 | 0 | 0 | 0 | 0 | 1.56B | 0 | 0 | 0 | 2.15B | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | — | — | — | — | 0 | 0 |
| Financing Cash Flow | -410.00M | -260.00M | -184.00M | -104.00M | -340.00M | 233.00M | 214.00M | 7.00M | 24.00M | 1.57B | 15.00M | 16.00M |
| Net Change in Cash | -890.00M | -504.00M | 671.00M | 735.00M | -179.00M | 314.00M | -2.04B | -412.00M | 565.00M | 1.44B | -77.00M | 513.00M |
| Free Cash Flow | 1.28B | 171.00M | 1.01B | 1.16B | 1.13B | 354.00M | 1.18B | 823.00M | 658.00M | -15.00M | 690.00M | 508.00M |
This table shows 12 quarterly periods of Boston Scientific's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow BSX's reporting calendar. What is a cash flow statement?